Centany

NDA 50788, held by Padagis US. Mupirocin.

As of Nov 14, 2026, NDA 50788 (Centany), held by Padagis US, was first approved by FDA on Dec 4, 2002, with 3 approved supplements and 0 published complete response letters.

First approved: Dec 4, 2002
Review: Standard
Supplements approved: 3
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 4 submissions below

Date	Submission	Status	Documents
Dec 4, 2002	Original applicationNew dosage form · Standard review	Approved	Review Letter Label

Products

1 strengths and forms

Product	Active ingredient	Marketing
Centany2% · ointment;topical	Mupirocin	Discontinued

All 4 submissions, including labeling and manufacturing supplements


Jul 10, 2025	Supplement 9Labeling · Standard review	Approved	Letter Label
Jun 19, 2015	Supplement 5Labeling · Standard review	Approved	Label Letter
Sep 15, 2014	Supplement 4Manufacturing · Standard review	Approved	None posted
Dec 4, 2002	Original applicationNew dosage form · Standard review	Approved	Review Letter Label

Identifiers

Application: NDA 50788
Drugs@FDA: Overview at FDA
Company: Padagis US LLC

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters